Network meta-analysis
Systolic blood pressure change
Overweight or obesity without diabetes (adults)
weeks 20 to 40 (target week 26)Not stated by the trialsEach dose separatelyMean differenceConvergence criteria not all met
7
Randomized trials
16
Treatments
1,330
Participants
23
Trial arms
In plain language
Across 7 trials with 1,330 participants, 0 of 15 treatments had a clearly better result than placebo on systolic blood pressure change, and for 15 the evidence could not tell them apart from placebo. The most favorable estimate was for Mazdutide 6 mg subcutaneous once weekly: mean difference -9.61 mmHg (95% credible interval -18.70 to 0.87).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Mean difference in mmHg. Lower values favor the treatment.
| Treatment | Bayesian MD (95% CrI) | 95% prediction interval | Frequentist MD (95% CI) | Verdict |
|---|---|---|---|---|
| Mazdutide 6 mg subcutaneous once weekly MAZD_SC_6MG_QW | -9.61 (-18.70 to 0.87) | -22.92 to 5.44 | -9.80 (-13.13 to -6.47) | Unclear |
| Semaglutide 2.4 mg subcutaneous once weekly SEMA_SC_2p4MG_QW | -6.94 (-18.90 to 5.51) | -22.23 to 9.36 | -7.18 (-15.83 to 1.47) | Unclear |
| Exenatide extended release and dapagliflozin 2 to 10 mg injection once weekly EXENER_SC_2-10MG_QW | -6.64 (-17.50 to 4.71) | -21.31 to 8.43 | -6.80 (-12.53 to -1.07) | Unclear |
| Liraglutide 2.4 mg injection once daily LIRA_SC_2p4MG_QD | -6.45 (-15.65 to 2.63) | -19.90 to 6.96 | -6.35 (-9.98 to -2.72) | Unclear |
| Efpeglenatide 6 mg subcutaneous once weekly EFPE_SC_6MG_QW | -5.86 (-15.20 to 4.13) | -19.43 to 8.11 | -6.00 (-9.75 to -2.25) | Unclear |
| Mazdutide 4.5 mg subcutaneous once weekly MAZD_SC_4p5MG_QW | -4.95 (-14.30 to 5.32) | -18.13 to 9.22 | -5.10 (-8.43 to -1.77) | Unclear |
| Liraglutide 3.0 mg subcutaneous once daily LIRA_SC_3p0MG_QD | -4.45 (-12.56 to 2.75) | -17.03 to 7.57 | -3.92 (-7.09 to -0.76) | Unclear |
| Mazdutide 3 mg subcutaneous once weekly MAZD_SC_3MG_QW | -4.07 (-13.48 to 6.37) | -17.49 to 10.56 | -4.20 (-7.67 to -0.73) | Unclear |
| Liraglutide 1.2 mg subcutaneous once daily LIRA_SC_1p2MG_QD | -3.45 (-12.97 to 5.82) | -17.32 to 10.13 | -3.35 (-6.82 to 0.11) | Unclear |
| Efpeglenatide 4 mg subcutaneous once weekly EFPE_SC_4MG_QW | -3.28 (-12.87 to 7.07) | -16.81 to 10.70 | -3.40 (-7.15 to 0.35) | Unclear |
| Efpeglenatide 8 mg injection every 2 weeks EFPE_SC_8MG_Q2W | -2.70 (-12.28 to 7.21) | -16.57 to 11.94 | -2.90 (-6.65 to 0.85) | Unclear |
| Liraglutide 1.8 mg subcutaneous once daily LIRA_SC_1p8MG_QD | -2.16 (-11.63 to 7.35) | -16.05 to 11.21 | -2.05 (-5.78 to 1.68) | Unclear |
| Orlistat ORLISTAT | -1.72 (-10.95 to 7.75) | -15.12 to 11.50 | -1.55 (-4.97 to 1.87) | Unclear |
| Semaglutide 1.0 mg subcutaneous once weekly SEMA_SC_1p0MG_QW | -1.40 (-11.31 to 8.37) | -14.98 to 12.75 | -1.38 (-4.98 to 2.22) | Unclear |
| Efpeglenatide 6 mg injection every 2 weeks EFPE_SC_6MG_Q2W | -0.04 (-9.47 to 9.54) | -13.59 to 13.70 | -0.20 (-3.95 to 3.55) | Unclear |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: mean difference of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | MAZD_SC_6MG_QW | SEMA_SC_2p4MG_QW | EXENER_SC_2-10MG_QW | LIRA_SC_2p4MG_QD | EFPE_SC_6MG_QW | MAZD_SC_4p5MG_QW | LIRA_SC_3p0MG_QD | MAZD_SC_3MG_QW | LIRA_SC_1p2MG_QD | EFPE_SC_4MG_QW | EFPE_SC_8MG_Q2W | LIRA_SC_1p8MG_QD | ORLISTAT | SEMA_SC_1p0MG_QW | EFPE_SC_6MG_Q2W |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 9.61 -0.87 to 18.70 | 6.94 -5.51 to 18.90 | 6.64 -4.71 to 17.50 | 6.45 -2.63 to 15.65 | 5.86 -4.13 to 15.20 | 4.95 -5.32 to 14.30 | 4.45 -2.75 to 12.56 | 4.07 -6.37 to 13.48 | 3.45 -5.82 to 12.97 | 3.28 -7.07 to 12.87 | 2.70 -7.21 to 12.28 | 2.16 -7.35 to 11.63 | 1.72 -7.75 to 10.95 | 1.40 -8.37 to 11.31 | 0.04 -9.54 to 9.47 |
| MAZD_SC_6MG_QW | -9.61 -18.70 to 0.87 | MAZD_SC_6MG_QW | -2.59 -17.55 to 13.68 | -2.97 -17.87 to 12.15 | -3.13 -15.62 to 10.97 | -3.76 -17.17 to 10.85 | -4.68 -14.05 to 5.37 | -5.13 -16.61 to 8.86 | -5.54 -15.52 to 4.29 | -6.12 -18.87 to 8.30 | -6.33 -19.55 to 8.00 | -6.86 -20.13 to 7.28 | -7.41 -20.45 to 6.74 | -7.84 -20.28 to 6.49 | -8.17 -21.99 to 6.55 | -9.53 -23.26 to 4.89 |
| SEMA_SC_2p4MG_QW | -6.94 -18.90 to 5.51 | 2.59 -13.68 to 17.55 | SEMA_SC_2p4MG_QW | -0.30 -17.23 to 16.25 | -0.48 -15.49 to 15.19 | -1.19 -16.63 to 14.58 | -1.98 -17.64 to 13.42 | -2.46 -15.73 to 12.64 | -2.94 -18.62 to 12.89 | -3.56 -18.30 to 11.96 | -3.73 -19.53 to 11.78 | -4.25 -19.88 to 11.87 | -4.86 -20.00 to 11.43 | -5.37 -20.12 to 10.33 | -5.52 -21.60 to 10.72 | -6.90 -22.69 to 8.58 |
| EXENER_SC_2-10MG_QW | -6.64 -17.50 to 4.71 | 2.97 -12.15 to 17.87 | 0.30 -16.25 to 17.23 | EXENER_SC_2-10MG_QW | -0.16 -13.99 to 14.14 | -0.91 -15.92 to 13.74 | -1.82 -16.88 to 12.81 | -2.27 -14.46 to 12.07 | -2.75 -17.26 to 12.20 | -3.21 -17.59 to 11.74 | -3.44 -18.61 to 11.37 | -3.89 -18.90 to 11.04 | -4.51 -18.09 to 9.79 | -4.93 -19.66 to 10.00 | -5.31 -20.06 to 9.54 | -6.61 -21.45 to 8.37 |
| LIRA_SC_2p4MG_QD | -6.45 -15.65 to 2.63 | 3.13 -10.97 to 15.62 | 0.48 -15.19 to 15.49 | 0.16 -14.14 to 13.99 | LIRA_SC_2p4MG_QD | -0.61 -14.83 to 12.23 | -1.52 -15.47 to 11.03 | -2.03 -11.33 to 7.79 | -2.48 -16.07 to 10.57 | -2.96 -13.30 to 7.76 | -3.18 -17.16 to 9.71 | -3.74 -18.13 to 8.79 | -4.27 -14.30 to 5.73 | -4.77 -14.97 to 5.71 | -5.07 -18.85 to 8.28 | -6.45 -20.14 to 6.84 |
| EFPE_SC_6MG_QW | -5.86 -15.20 to 4.13 | 3.76 -10.85 to 17.17 | 1.19 -14.58 to 16.63 | 0.91 -13.74 to 15.92 | 0.61 -12.23 to 14.83 | EFPE_SC_6MG_QW | -0.93 -14.78 to 12.31 | -1.40 -13.04 to 11.83 | -1.84 -15.88 to 11.82 | -2.39 -15.60 to 11.79 | -2.61 -12.60 to 7.62 | -3.09 -13.75 to 7.04 | -3.68 -17.05 to 10.50 | -4.15 -17.09 to 10.39 | -4.50 -17.89 to 9.70 | -5.83 -16.01 to 4.45 |
| MAZD_SC_4p5MG_QW | -4.95 -14.30 to 5.32 | 4.68 -5.37 to 14.05 | 1.98 -13.42 to 17.64 | 1.82 -12.81 to 16.88 | 1.52 -11.03 to 15.47 | 0.93 -12.31 to 14.78 | MAZD_SC_4p5MG_QW | -0.51 -11.64 to 13.18 | -0.84 -11.19 to 9.15 | -1.52 -14.01 to 12.87 | -1.73 -14.99 to 12.17 | -2.19 -15.36 to 11.47 | -2.75 -15.62 to 10.76 | -3.27 -15.76 to 10.59 | -3.58 -16.73 to 11.02 | -4.91 -17.90 to 9.22 |
| LIRA_SC_3p0MG_QD | -4.45 -12.56 to 2.75 | 5.13 -8.86 to 16.61 | 2.46 -12.64 to 15.73 | 2.27 -12.07 to 14.46 | 2.03 -7.79 to 11.33 | 1.40 -11.83 to 13.04 | 0.51 -13.18 to 11.64 | LIRA_SC_3p0MG_QD | -0.52 -13.79 to 11.34 | -0.94 -11.15 to 8.54 | -1.20 -14.29 to 10.60 | -1.67 -15.07 to 9.66 | -2.28 -12.17 to 6.60 | -2.71 -13.13 to 6.42 | -2.98 -15.87 to 8.81 | -4.37 -17.54 to 7.22 |
| MAZD_SC_3MG_QW | -4.07 -13.48 to 6.37 | 5.54 -4.29 to 15.52 | 2.94 -12.89 to 18.62 | 2.75 -12.20 to 17.26 | 2.48 -10.57 to 16.07 | 1.84 -11.82 to 15.88 | 0.84 -9.15 to 11.19 | 0.52 -11.34 to 13.79 | MAZD_SC_3MG_QW | -0.53 -13.72 to 13.47 | -0.77 -14.51 to 13.07 | -1.30 -15.18 to 12.44 | -1.86 -15.04 to 12.24 | -2.36 -15.23 to 11.67 | -2.62 -16.11 to 12.04 | -4.00 -17.71 to 10.40 |
| LIRA_SC_1p2MG_QD | -3.45 -12.97 to 5.82 | 6.12 -8.30 to 18.87 | 3.56 -11.96 to 18.30 | 3.21 -11.74 to 17.59 | 2.96 -7.76 to 13.30 | 2.39 -11.79 to 15.60 | 1.52 -12.87 to 14.01 | 0.94 -8.54 to 11.15 | 0.53 -13.47 to 13.72 | LIRA_SC_1p2MG_QD | -0.22 -14.24 to 13.32 | -0.65 -15.16 to 12.05 | -1.31 -11.69 to 9.15 | -1.80 -11.83 to 8.67 | -2.13 -16.08 to 11.64 | -3.42 -17.55 to 9.81 |
| EFPE_SC_4MG_QW | -3.28 -12.87 to 7.07 | 6.33 -8.00 to 19.55 | 3.73 -11.78 to 19.53 | 3.44 -11.37 to 18.61 | 3.18 -9.71 to 17.16 | 2.61 -7.62 to 12.60 | 1.73 -12.17 to 14.99 | 1.20 -10.60 to 14.29 | 0.77 -13.07 to 14.51 | 0.22 -13.32 to 14.24 | EFPE_SC_4MG_QW | -0.48 -10.68 to 9.40 | -1.08 -14.52 to 12.71 | -1.49 -14.74 to 12.11 | -1.83 -15.28 to 11.82 | -3.19 -12.75 to 6.30 |
| EFPE_SC_8MG_Q2W | -2.70 -12.28 to 7.21 | 6.86 -7.28 to 20.13 | 4.25 -11.87 to 19.88 | 3.89 -11.04 to 18.90 | 3.74 -8.79 to 18.13 | 3.09 -7.04 to 13.75 | 2.19 -11.47 to 15.36 | 1.67 -9.66 to 15.07 | 1.30 -12.44 to 15.18 | 0.65 -12.05 to 15.16 | 0.48 -9.40 to 10.68 | EFPE_SC_8MG_Q2W | -0.58 -13.62 to 13.45 | -1.02 -13.65 to 12.49 | -1.32 -14.66 to 12.43 | -2.71 -12.66 to 7.65 |
| LIRA_SC_1p8MG_QD | -2.16 -11.63 to 7.35 | 7.41 -6.74 to 20.45 | 4.86 -11.43 to 20.00 | 4.51 -9.79 to 18.09 | 4.27 -5.73 to 14.30 | 3.68 -10.50 to 17.05 | 2.75 -10.76 to 15.62 | 2.28 -6.60 to 12.17 | 1.86 -12.24 to 15.04 | 1.31 -9.15 to 11.69 | 1.08 -12.71 to 14.52 | 0.58 -13.45 to 13.62 | LIRA_SC_1p8MG_QD | -0.44 -10.50 to 9.62 | -0.72 -14.40 to 12.59 | -2.11 -16.02 to 11.27 |
| ORLISTAT | -1.72 -10.95 to 7.75 | 7.84 -6.49 to 20.28 | 5.37 -10.33 to 20.12 | 4.93 -10.00 to 19.66 | 4.77 -5.71 to 14.97 | 4.15 -10.39 to 17.09 | 3.27 -10.59 to 15.76 | 2.71 -6.42 to 13.13 | 2.36 -11.67 to 15.23 | 1.80 -8.67 to 11.83 | 1.49 -12.11 to 14.74 | 1.02 -12.49 to 13.65 | 0.44 -9.62 to 10.50 | ORLISTAT | -0.29 -13.58 to 12.98 | -1.67 -15.47 to 11.79 |
| SEMA_SC_1p0MG_QW | -1.40 -11.31 to 8.37 | 8.17 -6.55 to 21.99 | 5.52 -10.72 to 21.60 | 5.31 -9.54 to 20.06 | 5.07 -8.28 to 18.85 | 4.50 -9.70 to 17.89 | 3.58 -11.02 to 16.73 | 2.98 -8.81 to 15.87 | 2.62 -12.04 to 16.11 | 2.13 -11.64 to 16.08 | 1.83 -11.82 to 15.28 | 1.32 -12.43 to 14.66 | 0.72 -12.59 to 14.40 | 0.29 -12.98 to 13.58 | SEMA_SC_1p0MG_QW | -1.39 -14.90 to 12.46 |
| EFPE_SC_6MG_Q2W | -0.04 -9.47 to 9.54 | 9.53 -4.89 to 23.26 | 6.90 -8.58 to 22.69 | 6.61 -8.37 to 21.45 | 6.45 -6.84 to 20.14 | 5.83 -4.45 to 16.01 | 4.91 -9.22 to 17.90 | 4.37 -7.22 to 17.54 | 4.00 -10.40 to 17.71 | 3.42 -9.81 to 17.55 | 3.19 -6.30 to 12.75 | 2.71 -7.65 to 12.66 | 2.11 -11.27 to 16.02 | 1.67 -11.79 to 15.47 | 1.39 -12.46 to 14.90 | EFPE_SC_6MG_Q2W |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Frequentist check (netmeta)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting; the between designs Q above is the global check.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Baseline characteristics of the trials
The baseline value of each effect modifier or prognostic factor that applies here, per trial: mean or percent over arms, weighted by the number randomized. A note under a value names a stand in (a median for a mean, 100 minus the male share, Asian subgroup rows, an all Asian site list); "not reported" means no source of the trial prints it.
| Trial | Baseline BMI or body weight (kg/m2) effect modifier, prognostic factor; 7 of 7 |
|---|---|
| BARI-STEP S000434 | 41.5 |
| BARIOPTIMISE S000466 | 43.1 |
| NCT02075281 S000743 | 35.44 |
| NCT04904913 S001183 | 31.83 |
| Dapalost S001235 | 35.4 |
| HISTORI S001361 | 40.41 |
| NCT00422058 S001402 | 34.76 |
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagBaseline, Baseline BMI or body weight: design means range from 31.8 (MAZD_SC_3MG_QW vs MAZD_SC_4p5MG_QW vs MAZD_SC_6MG_QW vs PLACEBO) to 43.1 (LIRA_SC_3p0MG_QD vs PLACEBO) kg/m2; threshold 3
- FlagHeterogeneity, tau above threshold: tau 3.06 exceeds the outcome threshold 2; the flags of this network are candidate explanations
- NoteOutcome assessment, time point: selected time points span 20 to 32 weeks
- NoteOutcome assessment, analysis set: mixed: full_analysis 1, modified_itt 4, randomized 1, safety 1
- NoteRisk of bias, funding: mixed: industry 4, mixed 3
- NoteData handling, input conversions: n_randomized 4
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | intercurrent events (rescue) | blinding | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BARI-STEP | 32 | randomized | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2022 | age 18 to 65; at least 1 year after primary bypass or sleeve; less than 20 percent weight loss from surgery |
| BARIOPTIMISE | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2018 | adults at least 1 year after RYGB or sleeve gastrectomy with 20 percent or less weight loss and suboptimal GLP-1 response |
| NCT02075281 | 20 | safety | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 64 years; BMI 30 to 42, or 27 to 30 with comorbidity; FPG below 7 mmol/L; HbA1c 6.5 percent or less; no diabetes |
| NCT04904913 | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2021 | Chinese adults 18 to 75; BMI 28 or more, or 24 or more with comorbidity or hyperphagia; no diabetes, HbA1c below 6.5 |
| Dapalost | 24 | full_analysis | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2014 | age 18 to 70; BMI 30 to 45 kg/m2; no diabetes |
| HISTORI | 30 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | mixed | 2022 | age 18 to 60; schizophrenia spectrum on SGA; BMI 27 or more; HbA1c 39 to 47 mmol/mol; no diabetes |
| NCT00422058 | 20 | modified_itt | not stated | not stated | not stated | not stated | not stated | not stated | double_blind | industry | 2007 | age 18 to 65; BMI 30 to 40; FPG below 7 mmol/L; no diabetes |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the mean difference on the analysis scale against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| BARI-STEP | A1 | PLACEBO | 32 | arm, change | 5.010 | 3.100 | 30 | R0014003:Supplement Table 3 | |
| BARI-STEP | A2 | SEMA_SC_2p4MG_QW | 32 | arm, change | -2.170 | 3.140 | 34 | R0014003:Supplement Table 3 | |
| BARIOPTIMISE | A1 | PLACEBO | 24 | arm, change | 2.340 | 3.346 | 32 | R0017334:Table 2 | |
| BARIOPTIMISE | A2 | LIRA_SC_3p0MG_QD | 24 | arm, change | -6.280 | 2.899 | 32 | R0017334:Table 2 | |
| NCT02075281 | A1 | PLACEBO | 20 | arm, change | -0.100 | 1.300 | 48 | R0011218:Supplement Table S7 | |
| NCT02075281 | A2 | EFPE_SC_4MG_QW | 20 | arm, change | -3.500 | 1.400 | 44 | R0011218:Supplement Table S7 | |
| NCT02075281 | A3 | EFPE_SC_6MG_QW | 20 | arm, change | -6.100 | 1.400 | 42 | R0011218:Supplement Table S7 | |
| NCT02075281 | A4 | EFPE_SC_6MG_Q2W | 20 | arm, change | -0.300 | 1.400 | 41 | R0011218:Supplement Table S7 | |
| NCT02075281 | A5 | EFPE_SC_8MG_Q2W | 20 | arm, change | -3.000 | 1.400 | 40 | R0011218:Supplement Table S7 | |
| NCT04904913 | A1 | MAZD_SC_3MG_QW | 24 | arm, change | -1.300 | 1.300 | 62 | R0016107:Table 3 | |
| NCT04904913 | A2 | MAZD_SC_4p5MG_QW | 24 | arm, change | -2.200 | 1.200 | 63 | R0016107:Table 3 | |
| NCT04904913 | A3 | MAZD_SC_6MG_QW | 24 | arm, change | -6.900 | 1.200 | 61 | R0016107:Table 3 | |
| NCT04904913 | A4 | PLACEBO | 24 | arm, change | 2.900 | 1.200 | 62 | R0016107:Table 3 | |
| Dapalost | A1 | EXENER_SC_2-10MG_QW | 24 | arm, change | -9.800 | 2.015 | 25 | n_randomized | R0025222:Table 1 |
| Dapalost | A2 | PLACEBO | 24 | arm, change | -3.000 | 2.117 | 25 | n_randomized | R0025627:Table 2 |
| HISTORI | A1 | SEMA_SC_1p0MG_QW | 30 | arm, change | -1.610 | 1.000 | 77 | n_randomized | R0014539:Table 2 |
| HISTORI | A2 | PLACEBO | 30 | arm, change | -0.230 | 1.538 | 77 | n_randomized | R0014539:Table 2 |
| NCT00422058 | A1 | PLACEBO | 20 | arm, change | -3.200 | 1.372 | 94 | registry:outcomes | |
| NCT00422058 | A2 | LIRA_SC_1p2MG_QD | 20 | arm, change | -6.100 | 1.183 | 88 | registry:outcomes | |
| NCT00422058 | A3 | LIRA_SC_1p8MG_QD | 20 | arm, change | -4.800 | 1.378 | 85 | registry:outcomes | |
| NCT00422058 | A4 | LIRA_SC_2p4MG_QD | 20 | arm, change | -9.100 | 1.304 | 89 | registry:outcomes | |
| NCT00422058 | A5 | LIRA_SC_3p0MG_QD | 20 | arm, change | -6.400 | 1.060 | 89 | registry:outcomes | |
| NCT00422058 | A6 | ORLISTAT | 20 | arm, change | -4.300 | 1.149 | 90 | registry:outcomes |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.